We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04539236
Recruitment Status : Recruiting
First Posted : September 4, 2020
Last Update Posted : September 30, 2022
Sponsor:
Collaborators:
Celgene
Bristol-Myers Squibb
Information provided by (Responsible Party):
Mikkael Sekeres, MD, University of Miami

Brief Summary:
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Drug: Lenalidomide Drug: Luspatercept Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Actual Study Start Date : November 9, 2021
Estimated Primary Completion Date : August 1, 2029
Estimated Study Completion Date : August 1, 2029

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Luspatercept + Lenalidomide Group

Phase 1B: Luspatercept will be administered at starting dose 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered in a dose escalation design between 3 cohorts to determine MTD (2.5 mg, 5 mg and 10 mg daily dose on a 21-day cycle). MTD will be defined as the dose level with 0 or 1 DLT out of 6 participants. MTD will be declared as the RP2D for the Phase II portion of the study.

Phase II: Luspatercept will be administered at 1.0 mg/kg and can be titrated to 1.33 and 1.75 mg/kg dependent on participant response. Lenalidomide will be administered with the RP2D daily for 21 days on a 21 day cycle.

Treatment with combination of Lenalidomide and Luspatercept will continue as long as a participant is deriving clinical benefit, in the opinion of the treating physician, for up to 5 years or until disease progression or treatment intolerance.

Drug: Lenalidomide
Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
Other Name: Revlimid

Drug: Luspatercept
Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
Other Names:
  • Reblozyl
  • ActRIIB-IgG
  • ACE-536
  • 1373715-00-4




Primary Outcome Measures :
  1. MTD/RP2D of Luspatercept combined with Lenalidomide [ Time Frame: Up to 15 weeks ]
    Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Luspatercept combined with Lenalidomide (reported in mg/kg) from Phase Ib portion of study

  2. DLT Rate for Phase Ib [ Time Frame: Up to 15 weeks ]
    DLT rate is defined as the percentage of participants with Dose Limiting Toxicities (DLT) as evaluated by treating physician using the National Cancer Center (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. DLTs are non-hematologic events grade 3 or higher that are at least possibly related to the investigational product and do not resolve to grade 1 or lower within 21 days.

  3. Percentage of participants with RBC-TI response [ Time Frame: Up to 5 years ]
    Red Blood Cell Transfusion Independence (RBC-TI) response is defined as participants who are RBC transfusion free over any consecutive 56-day period

  4. Toxicity Rate for Phase II [ Time Frame: Up to 5 years ]
    Toxicity rate is defined as the percentage of participants with treatment emergent adverse events (TE-AEs) as evaluated by treating physician using the National Cancer Center (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0


Secondary Outcome Measures :
  1. Percentage of participants with relevant reduction in RBC transfusion requirement [ Time Frame: Up to 5 years ]
    Participants with relevant reduction in RBC transfusion requirement will be defined as those participants whose total number of RBC units transfused has decreased by at least 4 units compared to the number transfused during the 8 weeks before study participation

  2. Percentage of participants with Erythroid Response [ Time Frame: Up to 5 years ]
    Hematologic Improvement Erythroid Response (HI-E) will bdefined as at least a 1.5 g/dl increase in serum hemoglobin from baseline

  3. Duration of RBC-TI [ Time Frame: Up to 5 years ]
    The length of time where participants are RBC transfusion free will be reported

  4. Percentage of participants with Platelet Response [ Time Frame: Up to 5 years ]

    Hematologic improvement Platelet response (HI-P) will be defined as:

    For participants with a serum baseline platelet count of > 20,000/mm3 at baseline: An absolute increase of ≥ 30,000/mm3 from baseline

    For participants with a serum platelet count ≤ 20,000/mm3 at baseline: An increase of at least 100% from baseline counts to a platelet count > 20,000/mm3.


  5. Percentage of participants with Neutrophil Response [ Time Frame: Up to 5 years ]
    Hematologic improvement of Neutrophil Response (HI-N) will be defined as a serum absolute neutrophil count (ANC) increase from baseline of at least 100%, and an absolute increase of > 500/mm3 from baseline.

  6. Percentage of participants experiencing a progression to higher-risk MDS or AML [ Time Frame: Up to 5 years ]
    Percentage of participants experiencing a progression to higher-risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

  7. Overall Survival (OS) [ Time Frame: Up to 5 years ]
    OS is calculated for all participants from the date of initial registration to date of death due to any cause. The follow-up for participants last known to be alive is censored at the date of last contact.

  8. Percentage of participants with RBC-TI lasting 16 weeks [ Time Frame: Up to 5 years ]
    Percentage of participants with RBC-TI lasting 16 weeks (112 days) will be assessed per the Blood 2019 position paper on defining response in lower-risk MDS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is ≥ 18 years of age the time of signing the informed consent form (ICF).
  2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  3. Documented diagnosis of MDS according to World Health Organization (WHO) / French-American-British (FAB) classification that meets International Prognostic Scoring System Revised (IPSS-R) classification (Greenberg, 2012) of very low, low, or intermediate risk disease; intermediate patients must have a blast percentage <5% to be enrolled.
  4. Refractory or intolerant to, or ineligible for, prior Erythropoiesis-stimulating agents (ESA) treatment, as defined by any one of the following:

    • Refractory to prior ESA treatment - documentation of non-response or response that is no longer maintained to prior ESA-containing regimen, either as single agent or combination (eg, with G-CSF); ESA regimen must have been either:

      • recombinant human erythropoietin (rHu EPO) ≥ 40,000 IU/week for at least 8 doses or equivalent; OR
      • darbepoetin alpha ≥ 200-500 μg Q1-3W for at least 4 doses or equivalent;
    • Intolerant to prior ESA treatment - documentation of discontinuation of prior ESA-containing regimen, either as single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an adverse event
    • ESA ineligible - Low chance of response to ESA based on endogenous serum erythropoietin level > 200 U/L for subjects not previously treated with ESAs
  5. If previously treated with ESAs, agents must have been discontinued ≥ 4 weeks prior to date of C1D1.
  6. Requires RBC transfusions, as documented by the following criteria:

    • average transfusion requirement of ≥ 2 units/8 weeks of packed Red Blood Cells (pRBC) s confirmed for a minimum of 16 weeks immediately preceding C1D1.
    • Hemoglobin levels at the time of or within 7 days prior to administration of a RBC transfusion must have been ≤ 10.0 g/dL for the transfusion to be counted towards meeting eligibility criteria. Red blood cell transfusions administered when Hgb levels were > 10.0 g/dL and/or RBC transfusions administered for elective surgery will not qualify as a required transfusion for the purpose of meeting eligibility criteria.
    • no consecutive 56-day period that was RBC transfusion-free during the 16 weeks immediately preceding C1D1.
  7. Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 (Appendix 1)
  8. Females of childbearing potential (FCBP), defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months), must:

    • Have two negative pregnancy tests (urine or serum) as verified by the Investigator prior to starting study therapy (unless the screening pregnancy test was done within 72 hours of C1D1). She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment.
    • If sexually active, agree to use, and be able to comply with, highly effective contraception without interruption, 5 weeks prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks after discontinuation of study therapy.
  9. Male subjects must:

    • Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (for example, polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks following investigational product discontinuation, even if he has undergone a successful vasectomy.
  10. Subject must have a negative Coronavirus Disease of 2019 (COVID-19) test completed ≤7 days prior to administration of protocol therapy.
  11. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

  1. Prior therapy with Lenalidomide.
  2. Previously treated with either luspatercept (ACE-536) or sotatercept (ACE-011)
  3. MDS associated with del 5q cytogenetic abnormality
  4. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding

    • iron deficiency to be determined by serum ferritin ≤ 15 μg/L and additional testing if clinically indicated (eg, calculated transferrin saturation [iron/total iron binding capacity ≤ 20%] or bone marrow aspirate stain for iron).
  5. Prior allogeneic stem cell transplant
  6. Known history of diagnosis of AML
  7. Use of any of the following within 4 weeks prior to C1D1:

    • anticancer cytotoxic chemotherapeutic agent or treatment
    • other RBC hematopoietic growth factors (eg, Interleukin-3)
    • investigational drug or device, or approved therapy for investigational use. If the half-life of the previous investigational product is known, use within 5 times the half-life prior to C1D1 or within 5 weeks, whichever is longer is excluded.
  8. Uncontrolled hypertension, defined as repeated elevations of diastolic blood pressure (DBP) ≥ 100 mmHg despite adequate treatment.
  9. Prior history of malignancies, other than MDS, unless the subject has been free of the disease (including completion of any active or adjuvant treatment for prior malignancy) for ≥ 1 year. However, subjects with the following history/concurrent conditions involving in situ cancer (or similar) are allowed:

    • Basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis (TNM) clinical staging system)
  10. Major surgery within 4 weeks prior to C1D1. Subjects must have completely recovered from any previous surgery prior to C1D1
  11. History of stroke, deep venous thrombosis (DVT), pulmonary or arterial embolism within 6 months prior to C1D1
  12. Pregnant or breastfeeding females
  13. Subject has any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that, in the opinion of the Investigator, would prevent the subject from participating in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04539236


Contacts
Layout table for location contacts
Contact: Mikkael Sekeres, MD 305-243-9974 mxs3108@miami.edu

Locations
Layout table for location information
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Mikkael Sekeres, MD    305-243-9974    mxs3108@miami.edu   
Principal Investigator: Mikkael Sekeres, MD         
Moffitt Cancer Center Not yet recruiting
Tampa, Florida, United States, 33612
Contact: Rami Komrokji, MD    813-745-4291    rami.komrokji@moffitt.org   
Principal Investigator: Rami Komrokji, MD         
United States, Maryland
Johns Hopkins University Not yet recruiting
Baltimore, Maryland, United States, 21287
Contact: Amy DeZern, MD    410-502-7208    adezern1@jhmi.edu   
Principal Investigator: Amy DeZern, MD         
United States, Massachusetts
Dana-Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Rich Stone, MD    617-632-2214    richard_stone@dfci.harvard.edu   
Principal Investigator: Rich Stone, MD         
United States, New York
Cornell University Not yet recruiting
New York, New York, United States, 10021
Contact: Gail Roboz, MD    646-962-2700    gar2001@med.cornell.edu   
Principal Investigator: Gail Roboz, MD         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Hetty Carraway, MD    216-218-6828    carrawh@ccf.org   
Principal Investigator: Hetty Carraway, MD         
Sponsors and Collaborators
Mikkael Sekeres, MD
Celgene
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Mikkael Sekeres, MD University of Miami
Layout table for additonal information
Responsible Party: Mikkael Sekeres, MD, Professor, University of Miami
ClinicalTrials.gov Identifier: NCT04539236    
Other Study ID Numbers: 20201503
CASE2920 ( Other Identifier: Case Comprehensive Cancer Center )
First Posted: September 4, 2020    Key Record Dates
Last Update Posted: September 30, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mikkael Sekeres, MD, University of Miami:
non-del(5q) MDS
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Bone Marrow Diseases
Hematologic Diseases
Lenalidomide
Luspatercept
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Hematinics